Diannexin decreases inflammatory cell infiltration into the islet graft, reduces β-cell apoptosis, and improves early graft function

Transplantation

Volumn 90, Issue 7, 2010, Pages 709-716

  Cheng, Elaine Y ^a   Sharma, Vijay K ^a   Chang, Christina ^a   Ding, Ruchuang ^a   Allison, Anthony C ^b   Leeser, David B ^a   Suthanthiran, Manikkam ^a   Yang, Hua ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b Alavita Inc   (United States)

Author keywords

Apoptosis drug effects; Diabetes mellitus; Diannexin therapeutic use; Experimental; Islet transplantation; Mice

Indexed keywords

DIANNEXIN; GAMMA INTERFERON; GLUCOSE; HEME OXYGENASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOCORTIN 5; MESSENGER RNA; PROTEIN BID; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CELL INFILTRATION; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION PROFILING; GLUCOSE BLOOD LEVEL; IMMUNOHISTOLOGY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION;

ANIMALS; ANNEXIN A5; APOPTOSIS; DIABETES MELLITUS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HEME OXYGENASE-1; HUMANS; INFLAMMATION; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; POLYMERASE CHAIN REACTION; RNA, MESSENGER; TREATMENT OUTCOME;

EID: 77957990554     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181ed55d8     Document Type: Article

References (32)

1. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free im-munosuppressive regimen. N Engl J Med 2000; 343: 230.
2. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318.
3. Harlan DM, Kenyon NS, Korsgren O, et al. Current advances and travails in islet transplantation. Diabetes 2009; 58: 2175.
4. Barshes NR, Wyllie S, Goss JA. Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: Implications for in-trahepatic grafts. J Leukoc Biol 2005; 77: 587.
5. Morini S, Brown ML, Cicalese L, et al. Revascularization and remodelling of pancreatic islets grafted under the kidney capsule. J Anat 2007; 210: 565.
6. Carlsson P, Palm F, Andersson A, et al. Chronically decreased oxygen tension in rat pancreatic islets transplanted under the kidney capsule. Transplantation 2000; 69: 761.
7. Linn T, Schmitz J, Hauck-Schmalenberger I, et al. Ischaemiaislinked to inflammation and induction of angiogenesis in pancreatic islets. Clin Exp Immunol 2006; 144: 179.
8. Abdelli S, Ansite J, Roduit R, et al. Intracellular stress signaling pathways activated during human islet preparation and following acute cytokine exposure. Diabetes 2004; 53: 2815.
9. Bottino R, Balamurugan AN, Tse H, et al. Response of human islets to isolation stress and the effect of antioxidant treatment. Diabetes 2004; 53: 2559.
10. Thomas DA, Stauffer C, Zhao K, et al. Mitochondrial targeting with antioxidant peptide SS-31 prevents mitochondrial depolarization, reduces islet cell apoptosis, increases islet cell yield, and improves posttransplantation function. J Am Soc Nephrol 2007; 18: 213.
11. Kuypers FA, Larkin SK, Emeis JJ, et al. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 2007; 97: 478.
12. Shen XD, Ke B, Zhai Y, et al. Diannexin, a novel annexin V homodimer, protects rat liver transplants against cold ischemia-reperfusion injury. Am J Transplant 2007; 7: 2463.
13. Cooper M, Kapur S, Stratta R, et al. Diannexin, a novel ischemia/reperfu-sion therapeutic agent, reduces delayed graft function (DGF) in renal transplant recipients from marginal donors. Am J Transplant 2010; 10:S83.
14. Teoh NC, Ito Y, Field J, et al. Diannexin, a novel annexin V homodimer, provides prolonged protection against hepatic ischemia-reperfusion injury in mice. Gastroenterology 2007; 133: 632.
15. Molski M, Groth A, Allison AC, et al. Diannexin treatment decreases ischemia-reperfusion injury at the endothelial cell level of the microvascular bed in muscle flaps. Ann Plast Surg 2009; 63: 564.
16. Davalli AM, Scaglia L, Zangen DH, et al. Vulnerability of islets in the immediate posttransplantation period. Diabetes 1996; 45: 1161.
17. Heitmeier MR, Scarim AL, Corbett JA. Interferon-y increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin-1. J Biol Chem 1997; 272: 13697.
18. Arnush M, Heitmeier MR, Scarim AL, et al. IL-1 produced and released endogenously within human islets inhibits ß cell function. J Clin Invest 1998; 102: 516.
19. Balasa B, Gunst KV, Jung N, et al. IL-10 deficiency does not inhibit insulitis and accelerates cyclophosphamide-induced diabetes in the nonobese diabetic mouse. Cell Immunol 2000; 202: 97.
20. Pennline KJ, Roque-Gaffney E, Monohan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopathol 1994; 71: 169.
21. Camargo CA, Madden JF, Gao W, et al. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997; 26: 1513.
22. Choi S, Choi K, Yoon I, et al. IL-6 protects pancreatic islet beta cells from pro-inflammatory cytokines-induced cell death and functional impairment in vitro and in vivo. Transplant Immunol 2004; 13: 43.
23. Park H, Ahn Y, Park C, et al. Interleukin-6 protects MIN6 ß cells from cytokine-induced apoptosis. Ann N Y Acad Sci 2003; 1005: 242.
24. Teoh N, Field J, Farrell G. Interleukin-6 is a key mediator of the hepa-toprotective and pro-proliferative effects of ischaemic preconditioning in mice. J Hepatol 2006; 45: 20.
25. Selzner M, Camargo CA, Clavien P. Ischemia impairs liver regeneration alter major tissue loss in rodents: Protective effects of interleukin-6. Hepatology 1999; 30: 469.
26. Sun Z, Klein AS, Radaeva S, et al. In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology 2003; 125: 202.
27. Pileggi A, Molano RD, Berney T, et al. Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes 2001; 50: 1983.
28. Emamaullee JA, Shapiro AM. Interventional strategies to prevent ß-cell apoptosis in islet transplantation. Diabetes 2006; 55: 1907.
29. Thomas D, Yang H, Boffa DJ, et al. Proapoptotic Bax is hyperexpressed in isolated human islets compared with antiapoptotic Bcl-2. Transplantation 2002; 74: 1489.
30. Li H, Zhu H, Xu C, et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94:491.
31. Yang H, Thomas D, Boffa DJ, et al. Enforced c-Rel deficiency prolongs survival of islet allografts. Transplantation 2002; 74: 291.
32. Vermes I, Haanen C, Reutelingsperger C. Flow cytometry of apoptotic cell death. J Immunol Methods 2000; 243: 167.